Pets
“A peer-reviewed Cornell University study published in BMC Veterinary Research found that green tea extract inhibited cancer cell growth by 50% at specific lab concentrations across three canine cancer cell lines (mast cell, bone/osteosarcoma, and mammary cancer)." Headline version on the image: "GREEN TEA CUTS GROWTH OF DOG CANCER CELLS…”
Plain restatementA 2016 paper in BMC Veterinary Research, co-authored at Cornell University's College of Veterinary Medicine, tested a standardised green tea extract against three cultured canine tumour cell lines (C2 mastocytoma, D17 osteosarcoma, CMT-12 mammary carcinoma) and reported concentrations at which proliferation was reduced by half (IC50 values).
General information only - not veterinary advice.
The study is real. Researchers including two at Cornell's veterinary college published it in BMC Veterinary Research in 2016, and they did test a green tea extract against three canine tumour cell lines: mast cell, bone and mammary. The part left out is the authors' own verdict on those numbers. They wrote that the concentrations needed for green tea sat above what a living animal's body can reach, calling them supraphysiological, and their conclusion recommended turmeric and rosemary for further study instead of green tea. The material tested was a concentrated commercial extract dripped onto cells in a dish, not tea as a drink, and no dogs were treated in the study. The work was paid for by pet-food maker Royal Canin and two of the four authors worked there, which the post does not mention. What remains unknown is whether green tea extract does anything to a tumour in a living dog, because that has not been tested.
A [drifted from the evidence:] peer-reviewed Cornell University study published in BMC Veterinary Research [drifted from the evidence:] found that green tea extract [drifted from the evidence:] inhibited cancer cell growth by 50% at specific lab concentrations across three canine [drifted from the evidence:] cancer cell lines [drifted from the evidence:] (mast cell, bone/osteosarcoma, and mammary [drifted from the evidence:] cancer)." Headline version on the image: "GREEN TEA CUTS GROWTH OF DOG CANCER CELLS BY [drifted from the evidence:] 50% IN LAB TESTS.
A [added by the neutral restatement:] 2016 paper in BMC Veterinary Research, [added by the neutral restatement:] co-authored at Cornell University's College of Veterinary Medicine, tested a standardised green tea extract [added by the neutral restatement:] against three [added by the neutral restatement:] cultured canine [added by the neutral restatement:] tumour cell lines [added by the neutral restatement:] (C2 mastocytoma, D17 osteosarcoma, CMT-12 mammary [added by the neutral restatement:] carcinoma) and reported concentrations at which proliferation was reduced by [added by the neutral restatement:] half (IC50 values).
Red-tinted words in the claim drifted from the evidence. Green-tinted words are what a neutral restatement needs.
The trace / claim to source
- The study exists, is peer-reviewed, and was published in BMC Veterinary Research in August 2016 (volume 12, article 159).
- Cornell University College of Veterinary Medicine is the affiliation of two of the four authors, including the senior author.
- The three cell lines named in the claim match the study: C2 mastocytoma, D17 osteosarcoma and CMT-12 mammary carcinoma, all canine.
- Green tea extract was one of five extracts screened, and the abstract names green tea among the three most effective in the screening assay.
- IC50, the measure the study used, is by definition the concentration producing 50 percent inhibition of proliferation, so describing a 50 percent reduction "at specific lab concentrations" reflects what was measured. A 2025 review records a figure of 20.4 ug/mL on the mammary line.
- The claim and the headline both say "lab tests" and "cell lines," keeping the in-vitro frame rather than asserting a result in living dogs.
- The study says the concentrations at which green tea extract worked were above what a dog's body can reach. The authors wrote that the IC50 values for green tea and two other extracts were typically above 25 ug/mL, which they called supraphysiological, and that an animal cannot reach more than about 10 to 20 micromolar of these compounds even at large doses. Neither the claim nor the headline carries that sentence, and without it a reader is likely to take the 50 percent figure as something achievable by giving a dog green tea.
- The study's point was turmeric, not green tea. Turmeric extract was the most potent, with an IC50 below 13 ug/mL in all three lines, and the paper's conclusion recommends turmeric plus rosemary for further study. Green tea was placed with the extracts the authors set aside. Presenting green tea as the study's headline result reverses the paper's own emphasis.
- The headline says "green tea." The study used a standardised commercial leaf extract stated at 45.76 percent EGCG, a concentrated product, applied directly to cells in a dish. A brewed cup of tea is not that material, and nothing in the study tested tea as a drink.
- The work was funded by Royal Canin, a pet-food manufacturer, and two of the four authors worked for the funder. Describing it only as "a Cornell University study" omits that. The study's framing was explicitly about ingredients "which could be utilized in commercial dog food."
- Cells in a dish are not a dog. The study treated no live animals, measured no tumours, and reported no survival or remission outcome. "Cuts growth of dog cancer cells" is literally about cultured cells, but in a headline it reads as a statement about dogs with cancer.
- Whether a 50 percent inhibition concentration was actually established for green tea extract in all three lines, or in only some of them, could not be resolved. The paper gives a pooled statement ("typically above 25 ug mL-1") rather than three separately retrievable values, and the one figure located in a later review, 20.4 ug/mL, is for the mammary line only.
- Whether green tea extract has any effect on tumours in living dogs is unknown. No in-vivo canine cancer trial of green tea extract was located, and the authors themselves called for pharmacokinetic work before clinical use.
- Whether any independent, non-industry-funded group has reproduced this in-vitro result in canine tumour cells could not be established from the sources found.
- Safe and effective oral amounts are not established for this purpose. Separately, published toxicology in beagle dogs records vomiting, diarrhoea, severe systemic toxicity and deaths at high oral EGCG doses under fasting conditions, with liver and kidney necrosis at the top doses, so the amount given is not a neutral detail.
The study is real and is correctly named. It was published in BMC Veterinary Research on 2 August 2016. Two authors (Levine, Wakshlag) are at Cornell University College of Veterinary Medicine; two (Bayle, Biourge) are at the Royal Canin Research Center, Aimargues, France. Crossref records Royal Canin as the funder. The three cell lines are as described in the claim: C2 mastocytoma (mast cell), CMT-12 mammary gland carcinoma, and D17 osteosarcoma (bone). The green tea material was a Naturex green tea extract from Camellia sinensis leaf, stated at 45.76 percent EGCG purity, not brewed tea. Growth inhibition was measured by MTT proliferation assay, and IC50 (the concentration producing 50 percent inhibition) was the reported metric. So "inhibited growth by 50 percent at specific lab concentrations" is a fair description of what an IC50 is. The qualifier the claim leaves out is the authors' own assessment of those concentrations. The paper's abstract lists green tea, turmeric and rosemary as "the most effective" in the initial screen, but the results section then separates them: turmeric was the most potent, with an IC50 below 13 ug/mL in all three lines, while green tea was grouped with piperine and pomegranate, for which "Effective IC50 for these extracts across the cell lines were typically above 25 ug mL-1 which would be considered supraphysiological." The authors add that most animals cannot reach concentrations greater than roughly 10 to 20 micromolar of any specific bioactive component from these extracts even at relatively large doses. A 2025 review tabulating the same study lists green tea extract on CMT-12 cells at 20.4 ug/mL and marks the evidence "In vitro only." The paper's stated conclusion recommends further pre-clinical and clinical investigation of turmeric and rosemary in combination. It does not advance green tea as the promising finding, and the authors' own 2017 follow-up study pursued turmeric and rosemary.
Complete reasoning
The reply is formatted for pasting into the thread where the claim is circulating.
Ask this case
Answers come only from the case file above; nothing is added.
Is the study behind this claim real?
Yes. It was published in BMC Veterinary Research in August 2016, co-authored by researchers at Cornell University's College of Veterinary Medicine, and it tested a green tea extract against three canine cancer cell lines: mast cell, osteosarcoma, and mammary.
So does green tea really stop dog cancer cell growth by 50 percent?
The study did find concentrations of green tea extract that cut cell growth in half in lab dishes, which is what the IC50 measurement means. But the authors themselves said those concentrations were higher than a dog's body could realistically reach, calling them supraphysiological.
Was this tested on actual dogs drinking tea?
No. The study used a concentrated commercial green tea extract applied directly to cancer cells grown in a lab dish, not brewed tea, and no live dogs were treated or studied.
Why does the claim focus on green tea if the authors were more interested in something else?
The study found turmeric extract was the most potent of the ingredients tested, with lower effective concentrations than green tea, and the authors' conclusion called for further research on turmeric and rosemary, not green tea.
Does the claim mention who paid for the study?
No. The study was funded by Royal Canin, a pet food manufacturer, and two of the four authors worked for that company, a detail left out of the claim.